Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing–Remitting Multiple Sclerosis Patients? A Narrative Review-Reference-Cited by-同舟云学术

Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing–Remitting Multiple Sclerosis Patients? A Narrative Review

Published:2020-04-15 Issue:1 Volume:9 Page:55-66
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

AlSharoqi Isa Ahmed,Aljumah Mohamed,Bohlega Saeed,Boz Cavit,Daif Abdelkader,El-Koussa Salam,Inshasi Jihad,Kurtuncu Murat,Müller Thomas,Retief Chris,Sahraian Mohammad Ali,Shaygannejad Vahid,Slassi Ilham,Taha Karim,Zakaria Magd,Sørensen Per Soelberg

Funder

Merck Serono Middle East FZ-LLC

Publisher

Springer Science and Business Media LLC

Subject

Clinical Neurology,Neurology

Link

https://link.springer.com/content/pdf/10.1007/s40120-020-00187-3.pdf

Reference74 articles.

1. Shimizu Y, Ikeguchi R, Kitagawa K. When and how disease-modifying drugs for multiple sclerosis should be changed in daily practice. Clin Exp Immunol. 2017;8:71–80.

2. Zakaria M. Smoke and mirrors: Limited value of relative risk reductions for assessing the benefits of disease-modifying therapies for multiple sclerosis. Mult Scler Relat Disord. 2015;4:187–91.

3. Comi G, Radaelli M, Soelberg SP. Evolving concepts in the treatment of relapsing multiple sclerosis. Lancet. 2017;389:1347–56.

4. Burks JS. A practical approach to immunomodulatory therapy for multiple sclerosis. Phys Med Rehabil Clin N Am. 2005;16:449–66.

5. WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD index 2018. Available at https://www.whocc.no/atc_ddd_index. Accessed April 2020.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Neue Therapieansätze bei Multipler Sklerose inkl. Stellenwert älterer Präparate;Fortschritte der Neurologie · Psychiatrie;2024-01

2. Practical Guidance on the Use of Cladribine Tablets in the Management or Relapsing Multiple Sclerosis: Expert Opinion from Qatar;Degenerative Neurological and Neuromuscular Disease;2023-12

3. Risk of cancer with immunosuppressants compared to immunomodulators in multiple sclerosis: A nested case–control study within the French nationwide claims database;Pharmacoepidemiology and Drug Safety;2023-08-09

4. Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis;Neurology and Therapy;2023-06-29

5. Multicentre Observational Study of Treatment Satisfaction with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in the Arabian Gulf: The CLUE Study;Neurology and Therapy;2023-06-08